

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-15 (canceled)

Claim 16. **(currently amended)** A method of promoting growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof, said method comprising administering at least one promoter of growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof, wherein said at least one promoter includes ~~contains~~ Cofilin as an active ingredient and promotes growth or differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 17. **(currently amended)** A method of treating a disease that results from insufficient growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof, said method comprising administering at least one promoter of growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, wherein said at least one promoter includes ~~contains~~ Cofilin as an active ingredient and promotes growth or differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 18. **(currently amended)** The method of claim 17, wherein said disease comprises panhematopenia, a disease that is accompanied by hematopoietic hypofunction, ~~or a combination thereof.~~

Claim 19. **(currently amended)** A method of expanding hematopoietic stem cells *ex vivo* comprising administering ~~using~~ at least one promoter of growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof to the hematopoietic stem cells, wherein said at least one promoter includes ~~contains~~ Cofilin as an active ingredient and expands hematopoietic stem cells *ex vivo*.

Claim 20. **(currently amended)** A method of regenerative medicine comprising expanding hematopoietic stem cells *ex vivo* by administering ~~using~~ at least one promoter of growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a

combination thereof to the hematopoietic stem cells, and transplanting the expanded hematopoietic stem cells, wherein said at least one promoter includes ~~contains~~ Cofilin as an active ingredient.

Claim 21. **(currently amended)** The method of claim 16 or 17, wherein the Cofilin has the amino acid sequence depicted by SEQ ID NO:1 or the amino acid sequence of Cofilin depicted by SEQ ID NO:1 having the similar activity to Cofilin except that it has 1-5 ~~one or more~~ amino acid deletions, substitutions, additions, or a combination thereof, said Cofilin having the activity of promoting growth or ~~and~~ differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 22. **(currently amended)** The method of claim 16 or 17, wherein the Cofilin has the amino acid sequence depicted by SEQ ID NO:1 or an amino acid sequence having the similar activity to Cofilin encoded by a base sequence hybridizable at wash conditions consisting of 6 x SSC, 5 x Denhardt's, 0.1% SDS, at 45-68°C without formamide or 25-50°C with 50% formamide ~~under stringent conditions~~ with a base sequence complementary to the base sequence coding for the amino acid sequence of Cofilin depicted by SEQ ID NO:1, said Cofilin having the activity of promoting growth or ~~and~~ differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 23. **(currently amended)** The method of claim 16 or 17, wherein the Cofilin has the amino acid sequence depicted by SEQ ID NO:1 or an amino acid sequence having at least ~~30%~~ 70% amino acid sequence homology with the amino acid sequence of Cofilin (SEQ ID NO:1) and having the similar activity to Cofilin, said Cofilin having the activity of promoting growth or ~~and~~ differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 24. **(currently amended)** The method of claim 16 or 17, wherein the Cofilin is encoded by the base sequence depicted by SEQ ID NO:2 or a base sequence encoding an amino acid sequence having the similar activity to Cofilin which is hybridizable at wash conditions consisting of 6 x SSC, 5 x Denhardt's, 0.1% SDS, at 45-68°C without formamide or 25-50°C with 50% formamide ~~under stringent conditions~~ with a base sequence complementary to the base

sequence coding for the base sequence of Cofilin depicted by SEQ ID NO:2, said Cofilin having the activity of promoting growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 25. **(currently amended)** The method of claim 16 or 17, wherein the Cofilin is encoded by the base sequence depicted by SEQ ID NO:2 or DNA comprising a base sequence having at least ~~30%~~ 70% base sequence homology with the base sequence of Cofilin depicted by SEQ ID NO:2 which encodes an amino acid sequence having the similar activity to Cofilin, said Cofilin having the activity of promoting growth or [[,]] differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof.

Claim 26. (previously presented) The method of claim 16 or 17, wherein the Cofilin is produced by a gene recombinant technique.

Claim 27. (previously presented) The method of claim 16 or 17, wherein the Cofilin has a sugar chain.

Claim 28. **(currently amended)** The method of claim 16 or 17, which further includes ~~contains another~~ a cytokine other than Cofilin.

Claim 29. **(currently amended)** The method of claim 28, wherein said ~~another~~ cytokine other than Cofilin is ~~selected from the group consisting of~~ interleukin (IL)-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10 and IL-11, granulocyte colony stimulating factor (G-CSF), granulocyte/macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), erythropoietin (EPO), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), insulin-like growth factor (IGF), epidermal growth factor (EGF), hepatocyte growth factor (HGF), transforming growth factor- α (TGF- α), protease nexin I, protease nexin II, platelet derived growth factor (PDGF), cholinergic differentiation factor (CDF), leukocyte migration inhibitory factor (LIF), stem cell factor (SCF), flk-2/flt-3 ligand (FL), thrombopoietin (TPO), IL-6/soluble IL-6 receptor complex, Hyper IL-6 (fusion protein from IL-6 or ~~and~~ soluble IL-6 receptor), and any combinations thereof.

Claim 30. **(currently amended)** The method of claim 28, wherein said ~~another~~ cytokine other than Cofilin is IL-3.

Claim 31. **(currently amended)** The method of claim 28, wherein said ~~another~~ cytokine other than Cofilin comprises stem cell factor (SCF), flk-2/flt-3 ligand (FL), or a combination thereof.

Claim 32. **(currently amended)** The method of claim 16 or 17, wherein said promoter is for treating diseases that result from insufficient growth or ~~[[,]]~~ differentiation of hematopoietic stem cells, hematopoietic progenitors, ~~or a combination thereof.~~

Claim 33. **(currently amended)** The method of claim 16 or 17, wherein said promoter is for treating panhematopenia, diseases that are accompanied by hematopoietic hypofunction, ~~or a combination thereof.~~

Claim 34. **(currently amended)** The method of claim 16 or 17, wherein said promoter ~~can be used in~~ is for regenerative medicine comprising administering at least one promoter of growth or differentiation of hematopoietic stem cells, hematopoietic progenitors, or a combination thereof to the hematopoietic stem cells, wherein said at least one promoter includes Cofilin as an active ingredient.

Claim 35. (new) A method of promoting the growth or differentiation of hematopoietic stem cells, hematopoietic progenitor cells, or combination thereof, comprising administering human non-muscle type Cofilin to hematopoietic stem cells, hematopoietic progenitor cells, or combination thereof to promote growth or differentiation of said hematopoietic stem cells, hematopoietic progenitor cells, or combination thereof.

Claim 36. (new) The method of claim 35, wherein the human non-muscle type Cofilin is SEQ ID NO: 1.

Claim 37. (new) The method of claim 35, wherein the human non-muscle type Cofilin is encoded by SEQ ID NO: 2.